Navigation Links
NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State
Date:7/1/2009

NEW YORK, July 1 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS) announced today that it has raised additional gross funds of over $4 million from institutional and private investors. These funds, together with the $11 million private placement from three Asia-based investors announced April 13, 2009, bring the total investment obtained by NeoStem in the past two and half months to over $15 million. In addition, affiliates of Suzhou Erye Pharmaceuticals Company, Ltd. have increased their overall investment in the Company to over $1,000,000. As part of its China expansion activities, NeoStem is anticipating, subject to approval of its shareholders, on closing before year end on the acquisition of a 51% interest in Suzhou Erye through a merger with its current 51% owner.

The funds will be used to support NeoStem's continuing initiatives in VSEL (very small embryonic-like) stem cell technology licensed from the University of Louisville and to advance NeoStem's expansion activities in China, as well as other general corporate purposes. A portion of the funds also will be used to expand U.S.-based operations and add seasoned management to the NeoStem team with experience in clinical drug development in pharmaceutical and biotechnology industry and administration of overseas based clinical trials.

The terms and conditions of the current financing are the same as those of the earlier April round. Units are priced at $12.50 per unit, with each unit consisting of one share of the Company's Series D Convertible Redeemable Preferred Stock, convertible into ten shares of common stock and ten warrants each to purchase one share of common stock. The warrants have a per share exercise price equal to $2.50 and are callable by the Company if the common stock trades at a price equal to $3.50. Subject to the affirmative v
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NeoStem Featured in Business Week; Promising Adult Stem Cell Market Discussed in Fortune-CNNMoney.com Article
2. NeoStem Signs Agreement with Shanghai Corporation to Develop A Stem Cell Collection and Treatment Network in Shanghai, Taiwan and Other Targeted China Provinces
3. NeoStem, Inc. Appoints Financial Expert with Broad International Experience to the Board of Directors and to Serve as Chairman of the Companys Audit Committee
4. NeoStem Obtains Exclusive License to Innovative Stem Cell Procedure Treating Musculoskeletal Diseases
5. NeoStem Obtains Exclusive Worldwide License for Innovative Stem Cell Technology and Applications to Heal Chronic Wounds
6. NeoStem, Inc. Announces Agreement With Progenitor Cell Therapy, LLC
7. NeoStem Completes $11 Million Private Placement Financing to Support Expansion Activities in China, Further Development of NeoStems VSEL Technology and Advancement of Medical Tourism Initiatives
8. NeoStem Expands Stem Cell Collection Center Network Into New Jersey Led by Leading Plastic Surgeon and Anti-Aging Authority
9. NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies
10. NeoStem Receives Notice of Noncompliance from NYSE Alternext US
11. NeoStems New York City Adult Stem Cell Collection Center Has Opened and Begun Collections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... PA (PRWEB) March 31, 2015 Pittcon ... and Applied Spectroscopy, ended on March 12, in New ... at $21 million as estimated by the New Orleans ... more than 14,200 conferees and exhibitor personnel. Those ... of the conferee number. For the third year, the ...
(Date:3/31/2015)... NEW YORK , March 31, ... ), a biopharmaceutical company advancing protein biologic therapies ... its Korean marketing partner, Hanmi Pharmaceutical Co., Ltd ... Korea from the country,s Ministry of Food and ... Research Institute (KTR) for MuGard, its oncology supportive-care ...
(Date:3/31/2015)... 31, 2015 Lighthouse Information Systems, ... operations in California, Oregon, Washington and clients across ... Merger and Acquisition (M&A) Integration Services offering, effective ... Client Services and M&A Integration Practice Leader at ... vast majority of M&A initiatives fail to achieve ...
(Date:3/30/2015)... Calif. , March 30, 2015  NuGene ... its subsidiary corporation, NuGene BioPharma, Inc. has added ... Dr. Guan is an internationally recognized ... finishing his college education at Peking University, ... Ph.D. degree from the University of North Carolina, ...
Breaking Biology Technology:Pittcon 2015 Hits the Big Easy in a Big Way 2Pittcon 2015 Hits the Big Easy in a Big Way 3Pittcon 2015 Hits the Big Easy in a Big Way 4PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea 2PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea 3Lighthouse Information Systems, Inc., Announces Addition of M&A Integration Services 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 3
... CALGARY, April 16 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") ... his research group at St. James,s University Hospital ... in the April 10 online issue of,Gene Therapy. ... by,Oncolytic Reovirus for the Treatment of Melanoma.", ...
... Technology (NIST), in collaboration with the National Aeronautics ... for making essential measurements on samples of single-walled ... current best practices for characterizing one of the ... generation of nanoscale materials. , The nanotubes are ...
... Inc. (Nasdaq: VION ) today announced that it ... The Nasdaq Capital Market,listing requirements, including the time frame ... announced that it had received a letter, dated,March 24, ... Company,that it does not comply with Marketplace Rule 4310(c ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces Gene Therapy Publication on Reovirus Treatment for Melanoma 2Carbon nanotube measurements: latest in NIST 'how-to' series 2Vion Pharmaceuticals Files Plan With Nasdaq 2Vion Pharmaceuticals Files Plan With Nasdaq 3
(Date:3/17/2015)... , March 17, 2015 ... company specializing in clinical study management systems, is ... in attendance at ARENA,s Outsourcing in Clinical Trials ... This event provides an excellent forum for MedNet ... flexible and affordable software-as-a-service (SaaS) eClinical technology platform. ...
(Date:3/16/2015)... Between 16 and 20 ... innovations in biometric identification at the CeBIT exhibition ...      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ) , ... at the forefront: the company,s all new BiometricGate ... Germany . BiometricGate is the first ...
(Date:3/12/2015)... 2015 Beta Systems today ... access management (IAM) solution for a fixed price ... System,s new IAM package, customers benefit from the ... multiple IAM implementations across different industries. The new ... as any necessary services and consulting. It spans ...
Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2
... A prominent problem in AIDS is a form of ... normal movements. Scientists at the Burnham Institute for ... normal replication of stem cells in the adult brain, ... Lipton, Marcus Kaul, Shu-ichi Okamoto and their colleagues uncovered ...
... pathology underlying a recently identified neurological disorder that ... in the same gene that causes fragile X ... males, usually in their 50s, causing Parkinsons-like symptoms ... manifests itself from birth and is the most ...
... Scientists have discovered a key protein in the toxic ... (FXTAS), an inherited neurodegenerative disorder. The finding, in ... the complex mechanisms of FXTAS and lead scientists to ... will be published in the Aug. 16 issue of ...
Cached Biology News:AIDS interferes with stem cells in the brain 2AIDS interferes with stem cells in the brain 3Deep into the machinery of adult fragile X 2Deep into the machinery of adult fragile X 3Scientists link fragile X tremor/ataxia syndrome to binding protein in RNA 2
Mouse polyclonal antibody raised against a partial recombinant KCTD13. NCBI Entrez Gene ID = 253980...
Mouse monoclonal antibody raised against a partial recombinant SCARB2. NCBI Entrez Gene ID = SCARB2...
Mouse monoclonal antibody raised against a partial recombinant FAAH. NCBI Entrez Gene ID = FAAH...
Alpha-2-antiplasmin precursor (Alpha-2-plasmin inhibitor) (Alpha-2-PI) (Alpha-2-AP). [Source:Uniprot/SWISSPROT;Acc:P08697] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: